Drug intelligence / Profile preview

NBG040

Development stage: Preclinical
Lead developer: NB Health Laboratory
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

NBG040 is a preclinical-stage monoclonal antibody developed by NB Health Laboratory. It is designed to target a lipid G-protein coupled receptor (GPCR) and acts as an antagonist. The antibody is being developed for the treatment of severe infectious diseases (severe infections), leveraging NB Health Laboratory's proprietary MoGRAA Discovery Engine, which specializes in generating functional monoclonal antibodies against GPCRs, particularly those with lipid mediator ligands.

Beyond the preview

Go deeper on NBG040.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NBG040.

Explore the full profile